To date, only nonembryonic human stem cells have been used in cell-based gene therapy studies. The inherent limitations of these stem cells, as discussed below, have prompted scientists to ponder and explore whether human embryonic stem cells might overcome the current barriers to the clinical success of cell-based gene therapies.
Gene therapy is a relatively recent, and still highly experimental, approach to treating human disease. While traditional drug therapies involve the administration of chemicals that have been manufactured outside the body, gene therapy takes a very different approach: directing a patient's own cells to produce and deliver a therapeutic agent. The instructions for this are contained in the therapeutic transgene (the new genetic material introduced into the patient). Gene therapy uses genetic engineeringthe introduction or elimination of specific genes by using molecular biology techniques to physically manipulate genetic materialto alter or supplement the function of an abnormal gene by providing a copy of a normal gene, to directly repair such a gene, or to provide a gene that adds new functions or regulates the activity of other genes.
Clinical efforts to apply genetic engineering technology to the treatment of human diseases date to 1989. Initially, gene therapy clinical trials focused on cancer, infectious diseases, or disorders in which only a single gene is abnormal, such as cystic fibrosis. Increasingly however, efforts are being directed toward complex, chronic diseases that involve more than one gene. Prominent examples include heart disease, inadequate blood flow to the limbs, arthritis, and Alzheimer's disease.
The potential success of gene therapy technology depends not only on the delivery of the therapeutic transgene into the appropriate human target cells, but also on the ability of the gene to function properly in the cell. Both requirements pose considerable technical challenges.
Gene therapy researchers have employed two major strategies for delivering therapeutic transgenes into human recipients (see Figure 11.1. Strategies for Delivering Therapeutic Transgenes into Patients). The first is to "directly" infuse the gene into a person. Viruses that have been altered to prevent them from causing disease are often used as the vehicle for delivering the gene into certain human cell types, in much the same way as ordinary viruses infect cells. This delivery method is fairly imprecise and limited to the specific types of human cells that the viral vehicle can infect. For example, some viruses commonly used as gene-delivery vehicles can only infect cells that are actively dividing. This limits their usefulness in treating diseases of the heart or brain, because these organs are largely composed of nondividing cells. Nonviral vehicles for directly delivering genes into cells are also being explored, including the use of plain DNA and DNA wrapped in a coat of fatty molecules known as liposomes.
Figure 11.1. Strategies for Delivering Therapeutic Transgenes into Patients.
( 2001 Terese Winslow)
The second strategy involves the use of living cells to deliver therapeutic transgenes into the body. In this method, the delivery cellsoften a type of stem cell, a lymphocyte, or a fibroblastare removed from the body, and the therapeutic transgene is introduced into them via the same vehicles used in the previously described direct-gene-transfer method. While still in the laboratory, the genetically modified cells are tested and then allowed to grow and multiply and, finally, are infused back into the patient.
Gene therapy using genetically modified cells offers several unique advantages over direct gene transfer into the body and over cell therapy, which involves administration of cells that have not been genetically modified. First, the addition of the therapeutic transgene to the delivery cells takes place outside the patient, which allows researchers an important measure of control because they can select and work only with those cells that both contain the transgene and produce the therapeutic agent in sufficient quantity. Second, investigators can genetically engineer, or "program," the cells' level and rate of production of the therapeutic agent. Cells can be programmed to steadily churn out a given amount of the therapeutic product. In some cases, it is desirable to program the cells to make large amounts of the therapeutic agent so that the chances that sufficient quantities are secreted and reach the diseased tissue in the patient are high. In other cases, it may be desirable to program the cells to produce the therapeutic agent in a regulated fashion. In this case, the therapeutic transgene would be active only in response to certain signals, such as drugs administered to the patient to turn the therapeutic transgene on and off.
To date, about 40 percent of the more than 450 gene therapy clinical trials conducted in the United States have been cell-based. Of these, approximately 30 percent have used human stem cellsspecifically, blood-forming, or hematopoietic, stem cellsas the means for delivering transgenes into patients.
Continued here:
11. Use of Genetically Modified Stem Cells in Experimental ...
- Carson City School District experiencing teacher shortage; nationwide data points to burnout, low pay and behavior issues as culprits - Carson Now - September 8th, 2022
- Get Healthy Carson City: Breastfeeding benefits a baby's health - Nevada Appeal - August 5th, 2022
- Promising solution to fatal genetic-disorder complications discovered by University professor and Ph.D. candidate - Nevada Today - July 19th, 2022
- Anosmia in COVID-19: Underlying Mechanisms and Assessment ... - November 22nd, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 16th, 2021
- When aid-in-dying means you have to go before youre ready - Monterey Herald - August 31st, 2021
- BioRestorative Therapies Discusses Upcoming Annual Meeting - GlobeNewswire - August 18th, 2021
- Contrasting Mesoblast (NASDAQ:MESO) and Titan Pharmaceuticals (NASDAQ:TTNP) - Riverton Roll - February 2nd, 2020
- Nevada cancer survivor found to have two different sets of DNA after bone marrow transplant 4 years ago - MEAWW - January 20th, 2020
- Distinguished Efforts to Advance Science | The UCSB Current - The UCSB Current - November 28th, 2019
- Three Podcasts to Listen to in November - The New Yorker - November 5th, 2019
- Comparison of Spectrum Pharmaceuticals Inc. (SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly - November 5th, 2019
- Spectrum Pharmaceuticals Inc. (SPPI) and TG Therapeutics Inc. (NASDAQ:TGTX) Comparison side by side - MS Wkly - October 15th, 2019
- Spectrum Pharmaceuticals Inc. (SPPI) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) Comparison side by side - CryptoCoinsTribune - September 22nd, 2019
- Stem Cell Therapy | Las Vegas, NV - September 10th, 2019
- Yolanda Hadids Lyme Disease Battle - Nevada Stem Cell ... - April 18th, 2019
- Regenerative Medicine Institute of Nevada RMinLasVegas ... - November 1st, 2018
- Las Vegas Stem Cells Treatment, Nevada, Legal, Reno, Mogul ... - September 24th, 2017
- New Face: Janice Pluth - UNLV NewsCenter - August 28th, 2017
- Cody Garbrandt Likely Won't Return Until at Least November - MMA News - July 7th, 2017
- Regenexx Las Vegas | Nevada's Regenexx Provider - July 6th, 2017
- Our Team - Stem Cell Therapy in Reno NV - July 6th, 2017
- Dynamic Stem Cell Therapy | Stem Cell Therapy Nevada - July 6th, 2017
- Stem Cell Therapy Reno NV - Sierra Stem Cell Institute - July 6th, 2017
- Digital Scholarship@UNLV - University of Nevada, Las Vegas - November 12th, 2016
- Regenerative Medicine | Nevada Pain - Las Vegas, Henderson - October 9th, 2016
- Facts About Abortion: Stem Cell Research and Abortion - October 19th, 2015
- Regenerative Cell Institute Las Vegas | Stem Cell Therapy ... - July 2nd, 2015
- Stem Cell Therapies News - World Stem Cells, LLC - March 13th, 2015
- Experimental research turns out well for local man - November 5th, 2014
- An update review of stem cell applications in burns and ... - October 27th, 2014
- Portola volunteer firefighter battles leukemia - October 24th, 2014
- vegas | The Stem Cell Blog - September 29th, 2014
- Stem-Cell Therapy and Repair after Heart Attack and Heart ... - September 27th, 2014
- Dr. Foulk - Welcome to Nevada Center for Reproductive Medicine - September 27th, 2014
- Patients guide to treatments | Knoepfler Lab Stem Cell Blog - September 27th, 2014
- Nevada Stem Cell Treatment | Stem Cell Treatments - September 7th, 2014
- Stem Cell Therapy News, Stories | Regenerative Medicine ... - August 29th, 2014
- Nevada (Stem Cell) - what-when-how - August 22nd, 2014